Thu, Aug 21, 2014, 7:30 AM EDT - U.S. Markets open in 2 hrs.

Recent

% | $
Quotes you view appear here for quick access.

Neurocrine Biosciences Inc. Message Board

  • nowwheretogo22004 nowwheretogo22004 Sep 19, 2012 4:10 PM Flag

    No upcoming milestone news

    Since there is no news coming out on the product pipeline until late 2013, we got a verdict today on how the stock is going to behave. Even after that nice Seeking Alpha article, we couldn't maintain the $8 a share. It's a shame. I know I'll be justly rewarded within the next 18 months. I just don't see much of an opportunity to do any trading with this for now.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • What did i say....DEAD MONEY! I told you guys the trade..sell NBIX and buy goog,which i did @594 and now 732 a share only 20 shares but do the math($2,760 for you dummies)

      Sentiment: Strong Sell

    • We should get VMAT results by March or April 2013 and, if positive, it will provide a boost (at least 10 to 20% IMO and maybe more). After that, somehow, someway, we will get an indication of how the Fibroids trial went for Elagolix. My guess is around late next summer we will know something. Obviously, another potential booster if positive. I also believe there will be a run up prior to the VMAT results in anticipation. JMO.

      • 1 Reply to ashtonb22000
      • That's true. We could get VMAT results. Also, I do believe that some point in time this stock is going to make a run to 10 bucks a share out of the blue. Some big investors will start piling in prior to the anticipation of endometriosis, fibroids, VMAT2. All that I'm saying is that it sure doesn't look like that going to happen for a while. I'm not going to sell, because the run up would happen the week that I sell! It's tough right now not having any news to look to for the rest of the calendar year.

 
NBIX
15.28-0.31(-1.96%)Aug 20 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.